tradingkey.logo
tradingkey.logo
検索

Myriad Genetics Inc

MYGN
ウォッチリストに追加
5.990USD
-0.010-0.17%
終値 07/02, 13:00ET15分遅れの株価
565.46M時価総額
損失額直近12ヶ月PER

詳細情報 Myriad Genetics Inc 企業名

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.

Myriad Genetics Incの企業情報

企業コードMYGN
会社名Myriad Genetics Inc
上場日Oct 06, 1995
最高経営責任者「CEO」Raha (Samraat S)
従業員数2700
証券種類Ordinary Share
決算期末Oct 06
本社所在地322 North 2200 West
都市SALT LAKE CITY
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号84116
電話番号18015843600
ウェブサイトhttps://myriad.com/
企業コードMYGN
上場日Oct 06, 1995
最高経営責任者「CEO」Raha (Samraat S)

Myriad Genetics Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
296.53K
-58.32%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
267.80K
+58.57%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
191.84K
+31.12%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
171.89K
+26.01%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
93.72K
-36.29%
Dr. Dale Muzzey
Dr. Dale Muzzey
Chief Scientific Officer
Chief Scientific Officer
86.18K
-135.01%
Mr. Brian Donnelly
Mr. Brian Donnelly
Chief Commercial Officer
Chief Commercial Officer
59.05K
+8.47%
Mr. Benjamin Richard (Ben) Wheeler
Mr. Benjamin Richard (Ben) Wheeler
Chief Financial Officer
Chief Financial Officer
21.32K
-1299.87%
Ms. S. Louise Phanstiel, CPA
Ms. S. Louise Phanstiel, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Heiner Dreismann, Ph.D.
Dr. Heiner Dreismann, Ph.D.
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
296.53K
-58.32%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
267.80K
+58.57%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
191.84K
+31.12%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
171.89K
+26.01%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
93.72K
-36.29%
Dr. Dale Muzzey
Dr. Dale Muzzey
Chief Scientific Officer
Chief Scientific Officer
86.18K
-135.01%

よくある質問

Myriad Genetics Incの上位5名の株主は誰ですか?

Myriad Genetics Incの上位5名の株主は以下のとおりです。Mr. Mark S. Verratti

Myriad Genetics Inc(MYGN)の株式を保有している機関の数はいくつですか?

2026Q1時点で、Myriad Genetics Incの株式を保有している機関は539社あり、保有株式の総市場価値は約102.95Mで、全体の109.00%を占めています。2025Q4と比較して、機関の持ち株は-7290509.00増加しています。

Myriad Genetics Incの最大の収益源は何ですか?

2026Q1において、Hereditary Cancer部門がMyriad Genetics Incにとって最大の収益を生み出しており、その金額は372.40Mで、全収益の45.17%を占めています。